KRAS and adenocarcinoma: Adenocarcinomas accounted for 89% of all alterations, with <i>TP53</i> (21%) and <i>KRAS</i> (15%) being most common, while squamous cell carcinomas predominantly harbored <i>TP53</i> (38%) and <i>MET</i> (15%) mutations.